Literature DB >> 28687462

The effect of tiotropium in combination with olodaterol on house dust mite-induced allergic airway disease.

Gerrit John-Schuster1, Stan de Kleijn2, Yolanda van Wijck2, Veerle Kremer2, Hermelijn H Smits3, Michael P Pieper4, Pieter S Hiemstra2, Christian Taube2.   

Abstract

One of the major goals of asthma therapy is to maintain asthma control and prevent acute exacerbations. Long-acting bronchodilators are regularly used for the treatment of asthma patients and in clinical studies the anti-cholinergic tiotropium has recently been shown to reduce exacerbations in patients with asthma. So far it is unclear how tiotropium exerts this effect. For this purpose, we designed an allergen-driven rechallenge model of allergic airway inflammation in mice, to assess the effectiveness of tiotropium and the long-acting β-2 adrenoceptor agonist olodaterol on allergen-induced exacerbations of airway disease. Female C57BL/6J mice were sensitized intranasally (i.n.) with 1 μg of house dust mite (HDM) extract followed by a challenge regime (5 consecutive days 10 μg HDM extract i.n.) after one week. Mice were exposed to a secondary challenge five weeks after sensitization and were treated i.n. with different concentrations of tiotropium or olodaterol (1, 10 and 100 μg/kg) or a combination thereof (10 μg/kg each) prior to and during the secondary challenge period. Three days after the last challenge, bronchoalveolar lavage (BAL) fluid and lung tissue were collected for flow cytometry and histologic analysis, respectively. Secondary challenge with HDM extract strongly induced allergic airway disease reflected by inflammatory cell infiltration and goblet cell metaplasia. Treatment with tiotropium, but not with olodaterol reduced tissue inflammation and goblet cell metaplasia in a dose-dependent manner. The combination of tiotropium and olodaterol was more effective in significantly reducing tissue inflammation compared to tiotropium treatment alone, and also led to a decrease in BAL cell counts. These data suggest that in a model of relapsing allergic airway disease tiotropium directly prevents exacerbations by reducing inflammation and mucus production in the airways. In addition, the combination of tiotropium and olodaterol exerts synergistic effects.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Airway inflammation; Asthma; House dust mite; Olodaterol (PubChem CID: 11711522); Remodeling; Tiotropium; Tiotropium bromide (PubChem CID: 5487426)

Mesh:

Substances:

Year:  2017        PMID: 28687462     DOI: 10.1016/j.pupt.2017.06.010

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  4 in total

Review 1.  Muscarinic receptor antagonists and airway inflammation: A systematic review on pharmacological models.

Authors:  Luigino Calzetta; Elena Pistocchini; Beatrice Ludovica Ritondo; Francesco Cavalli; Francesca Camardelli; Paola Rogliani
Journal:  Heliyon       Date:  2022-06-22

Review 2.  The mode of action of anticholinergics in asthma.

Authors:  Reinoud Gosens; Nicholas Gross
Journal:  Eur Respir J       Date:  2018-10-04       Impact factor: 16.671

Review 3.  The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review.

Authors:  Luigino Calzetta; Angelo Coppola; Beatrice Ludovica Ritondo; Matteo Matino; Alfredo Chetta; Paola Rogliani
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-02-12

4.  Long-Term Exposure to Sulfur Dioxide Before Sensitization Decreased the Production of Specific IgE in HDM-Sensitized Allergic Rhinitis Mice.

Authors:  Maoyu Ye; Honghui Liu; Honglei Li; Qian Liu; Zheng Zhou; Tiansheng Wang; Guolin Tan
Journal:  J Inflamm Res       Date:  2022-04-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.